Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 15INDUSTRY 7NIH 3OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Kaposi 1Immune Reconstitution Inflammatory Syndrome 1Acquired Immunodeficiency Syndrome 1

Interventions

Cisplatin 50Capecitabine 42apatinib 34Radiotherapy 33Oxaliplatin 33Gemcitabine 33Cyclophosphamide 32Drug Therapy 31Paclitaxel 30Carboplatin 29tislelizumab 27Irinotecan 27Fluorouracil 26Docetaxel 26Bevacizumab 23Surgical Procedures, Operative 21Nivolumab 19pembrolizumab 18fludarabine 18Radiation 16Metformin 16Exercise 16camrelizumab 15S 1 (combination) 14Control Groups 14Blood Specimen Collection 14Pemetrexed 13Standard of Care 12anlotinib 11Neoadjuvant Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Valganciclovir × Clear all
NCT03296553 2022-01-27

Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

National Institute of Cancerología

Phase 2 Completed
40 enrolled 6 charts
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, Immune Reconstitution Inflammatory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡